Mathieu Grapin

Mathieu Grapin

Auto-generated profile, based on publicly available information

Mathieu Grapin

Department of Radiation Oncology, Unicancer-Georges-Francois Leclerc Cancer Center, 21079 Dijon, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2019 in Cancers
Verified
Journal Article
Open access
PDF file
JBJihane Boustani
Jihane Boustani
MGMathieu Grapin
Mathieu Grapin
PLPierre-Antoine Laurent
Pierre-Antoine Laurent
LALionel Apetoh
Lionel Apetoh
Céline MirjoletCéline Mirjolet
Céline Mirjolet
Historically, the 4Rs and then the 5Rs of radiobiology explained the effect of radiation therapy (RT) fractionation on the treatment efficacy. These 5Rs are: Repair, Redistribution, Reoxygenation, Repopulation and, more recently, intrinsic Radiosensitivity. Advances in radiobiology have demonstrated that RT is able to modify the tumor micro environment (TME) and to induce a local and systemic (abscopal effect) immune response. Conversely, RT is able to increase some immunosuppressive barriers, which can lead to tumor radioresistance. Fractionation and dose can affect the immunomodulatory properties of RT. Here, we review how fractionation, dose and timing shape the RT-induced anti-tumor immune response and the therapeutic effect of RT. We discuss how immunomodulators targeting immune checkpoint inhibitors and the cGAS/STING (cyclic GMP-AMP Synthase/Stimulator of Interferon Genes) pathway can be successfully combined with RT. We then review current trials evaluating the RT/Immunotherapy combination efficacy and suggest new innovative associations of RT with immunotherapies currently used in clinic or in development with strategic schedule administration (fractionation, dose, and timing) to reverse immune-related radioresistance. Overall, our work will present the existing evidence supporting the claim that the reactivation of the anti-tumor immune response can be regarded as the 6th R of Radiobiology.

1 April 2019 in European Journal of Radiology
Verified
Journal Article
Closed access
MGMathieu Grapin
Mathieu Grapin
CCCharles Coutant
Charles Coutant
JRJean-Marc Riedinger
Jean-Marc Riedinger
SLSylvain Ladoire
Sylvain Ladoire
FBFrançois Brunotte
François Brunotte
OHOlivier Humbert
Olivier Humbert

15 February 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MGMathieu Grapin
Mathieu Grapin
MQMagali Quivrin
Magali Quivrin
ABAurélie Bertaut
Aurélie Bertaut
EMEtienne Martin
Etienne Martin
LCLuc Cormier
Luc Cormier
GCGilles Créhange
Gilles Créhange
Introduction: External beam radiation therapy (EBRT) can cure localized prostate cancer (PCa) by sterilizing cancer cells in the prostate gland and surrounding tissues at risk of microscopic dissemination. We hypothesized that pelvic EBRT for localized PCa might have an unexpected prophylactic impact on the occurrence of pelvic bone metastases. Material and Methods: We reviewed the data of 332 metastatic PCa patients. We examined associations between the number (≤5 vs. >5) and the location of bone metastases (in-field vs. out-of-field), which occurred at first relapse, and a previous history of EBRT for PCa (EBRT vs. No-EBRT). Results: One hundred and ten patients M0 at baseline were eligible. Fifty-six patients (51%) were in the No-EBRT group, and 54 patients (49%) in the EBRT group. The proportion of patients who developed >5 bone metastases in the bony pelvis was higher in the No-EBRT group vs. the EBRT group: 10 patients (18%) vs. 2 patients (4%), respectively (p = 0.02). By multivariate analysis EBRT was associated with a lesser occurrence of patients who had >5 bone metastases in the bony pelvis (OR = 0.17 [95%CI, 0.04–0.87], p = 0.03). Time to occurrence of bone metastases ≥5 years (OR = 0.10 [95%CI, 0.05–0.19], p < 0.01), prior curative prostate treatment (OR = 0.58 [95%CI, 0.36–0.91], p = 0.02), >5 bone metastases in bony pelvis (OR = 2.61 [95%CI, 1.28–5.31], p < 0.01), >5 bone metastases out of bony pelvis (OR = 1.73 [95%CI, 1.09–2.76], p = 0.02) were all predictive of overall survival. Conclusion: Previous pelvic EBRT for PCa is associated with a lower number of pelvic bone metastases, which is associated with better overall survival.